Acumen Pharmaceuticals Presents Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease Acumen Pharmaceuticals Presents Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease
PRA Health Sciences Pioneers Connecting Clinical Trial Patients With Their Real World Data With Synoma PRA Health Sciences Pioneers Connecting Clinical Trial Patients With Their Real World Data With Synoma